-
-acting synthetic GLP-2 analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF), as well as several earlier stage assets. Building upon our
-
analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF), as well as several earlier stage assets. Building upon our history of GI
-
integrated biopharmaceutical team across External Innovation and Partnering, R&D, Manufacturing and Commercial operations collaborates. With Ipsen’s footprint in Cambridge, as a North America headquarters in
-
applications of neural networks to the analysis of multi-omic data, models for predicting phenotypes using genotype data, biological data integration, etc.. Participation in these projects will include
-
fully integrated biopharmaceutical team across External Innovation and Partnering, R&D, Manufacturing and Commercial operations collaborates. With Ipsen’s footprint in Cambridge, as a North America
-
fully integrated biopharmaceutical team across External Innovation and Partnering, R&D, Manufacturing and Commercial operations collaborates. With Ipsen’s footprint in Cambridge, as a North America
-
. 3. Theme 3 (“Human AI”): Knowledge-Integrated Human-Centered AI for Climate Resilience AI and data science systems that are guided by human knowledge or help guide models can generate insights and
-
applications of neural networks to the analysis of multi-omic data, models for predicting phenotypes using genotype data, biological data integration, etc.. Participation in these projects will include